Proceeds from the financing will be used to advance multiple gene
therapies from Avrobio's proprietary lentiviral platform, including the company's lead gene therapy, AVR-RD-01, currently in Phase 1 for Fabry disease, as well as three additional gene therapies for other lysosomal storage disorders, Gaucher disease, cystinosis and Pompe disease.
Its assay can analyse multiple gene
targets to evaluate their level of gene expression.
Our data suggests that dietary intake of the algal extract ProAlgaZyme and its specific sub-fractions result in an improved cholesterol distribution in hamsters, primarily via its effects on multiple gene
targets in the HDL (or reverse cholesterol transport) pathway," explained Dr.
Yet, university licensing practices can end up harming genetic testing laboratories at other universities, or preventing development of alternative tests that might offer improved accuracy, lower cost, or the ability to test for multiple gene
Scientists believe that various forms of FCD are due to multiple gene
We believe our 'multiple warhead' capability will allow us to understand more clearly those conditions that result from multiple gene
defects -- conditions such as Type II diabetes, autoimmune disorders, cardiovascular dysfunctions -- and perhaps also provide viable treatment regimes.
Professor Ernest Retzel, director of the Center for Computational Genomics and Bioinformatics, is developing a set of publicdomain Java visualization tools that can cull the results of multiple gene
research applications into a unified interface.
Data from the research collaboration shall be owned by both parties and could lead to commercial development of multiple gene
In a heavily pretreated group you'd expect them all to be dead long ago, but for our 24 patients who received multiple gene
transfer treatments, 12 of them lived more than 20 months and 3 are still alive more than 3 years after they entered the study," he said at the meeting.
Valentis' core technologies include multiple gene
delivery and gene expression systems and PEGylation technologies designed to improve the safety, efficacy and dosing characteristics of genes, proteins, peptides, peptidomimetics, antibodies, replicating and non replicating viruses and liposomes.
The company's core technologies include multiple gene
delivery and gene expression systems and PEGylation technologies designed to improve the safety, efficacy and dosing characteristics of genes, proteins, peptides, peptidomimetics, antibodies and replicating and non-replicating viruses.
The portfolio includes issued or granted patents for multiple gene
delivery systems, specific therapeutic genes and gene therapy applications and multiple genetically modified cell types used in gene therapy independent of the gene delivery system or therapeutic gene.